Remove 2026 Remove Healthcare Remove Side effects
article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted. Starting in 2026, the provision will affect 10 Part D drugs. Overactive bladder (OAB) is the final category primped for significant generic competition in 2023, Casberg said.

article thumbnail

NewAmsterdam goes public to advance drug in abandoned class

pharmaphorum

The Dutch biotech will book around $235 million from a private placement led by Frazier Healthcare Partners and Bain Capital Life Sciences and funds held in Frazier’s trust account. So why will obicetrapib avoid the pitfalls of its predecessors?